List of Excipients in Branded Drug ARRANON

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Novartis Pharmaceuticals Corporation	ARRANON	nelarabine	0078-0683	SODIUM CHLORIDE
Novartis Pharmaceuticals Corporation	ARRANON	nelarabine	0078-0683	WATER
Sandoz Inc	ARRANON	nelarabine	66758-165	SODIUM CHLORIDE
Sandoz Inc	ARRANON	nelarabine	66758-165	WATER

Arranon Excipient Strategy and Commercial Opportunities for Nelarabine

Last updated: August 24, 2026

Arranon is nelarabine, an intravenous purine nucleoside analog for relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Its commercial formulation is a simple, preservative-free aqueous solution containing nelarabine, sodium chloride, hydrochloric acid, and water for injection. The main opportunity is not a complex excipient patent strategy. It is a low-barrier sterile generic platform with improved packaging, pediatric dose handling, supply reliability, and potentially differentiated ready-to-use presentations. [1]

What excipients are used in Arranon?

Arranon injection contains nelarabine at 5 mg/mL in a sterile aqueous solution.

Formulation element	Arranon role	Commercial significance
Nelarabine	Active pharmaceutical ingredient	Small-molecule prodrug converted to ara-G
Sodium chloride	Tonicity adjustment	Standard injectable excipient with low regulatory risk
Hydrochloric acid	pH adjustment	Supports solution stability and pH control
Water for injection	Vehicle	Standard parenteral solvent
Preservative	Not listed in the U.S. label	Supports single-dose, oncology-use positioning
Container	Single-dose intravenous presentation	Packaging compatibility and extractables data remain relevant

The U.S. prescribing information specifies 50 mg of nelarabine in 10 mL of solution. The product is administered by intravenous infusion after dilution according to institutional procedures. [1]

The formulation has limited excipient complexity. It does not depend on lipids, surfactants, polymers, lyophilization, nanoparticles, or a proprietary delivery device. That reduces development risk but also limits the scope for strong formulation exclusivity.

What is the excipient strategy for Arranon?

The strongest strategy is to preserve the simple aqueous platform while improving attributes that matter to oncology pharmacies.

Maintain a low-risk aqueous formulation

A generic or follow-on nelarabine product should initially target the same formulation architecture:

• Nelarabine in water for injection
• Sodium chloride for tonicity
• Hydrochloric acid for pH adjustment
• Sterile, preservative-free single-dose packaging
• 5 mg/mL concentration unless a separate dosage-form strategy is justified

This approach minimizes formulation development, toxicology, extractables and leachables, and FDA comparability risk. A materially different excipient system would require additional stability, compatibility, impurity, and clinical-use justification without necessarily producing a meaningful market advantage.

Focus on pH and degradation control

The core technical work should establish:

• pH range during manufacture and shelf life
• Nelarabine assay and degradation-product profile
• Sensitivity to temperature excursions
• Light sensitivity
• Compatibility with common infusion diluents
• Adsorption to infusion bags and tubing
• Container closure integrity
• Hold time after dilution
• Freeze-thaw and shipping performance

For a small-molecule oncology injection, the commercial value of a formulation patent depends on demonstrating a measurable stability or administration advantage. A claim limited to routine pH adjustment, sodium chloride concentration, or water-for-injection composition would face substantial obviousness and prior-art risk.

Consider a ready-to-use presentation

A ready-to-use bag or pharmacy-ready container could reduce manipulation compared with a vial that requires withdrawal and dilution. The commercial benefits would include:

• Lower preparation time
• Fewer aseptic manipulations
• Reduced calculation and dilution errors
• Lower vial-transfer burden
• Better standardization across pediatric and adult oncology units
• Potential reduction in hazardous-drug handling steps

The main development issue is concentration and dose flexibility. Adult and pediatric dosing is based on body-surface area, so a fixed-dose bag may create overfill, wastage, or multiple-container requirements. A ready-to-use strategy is more attractive if the product can be supplied in several standardized strengths or volumes without creating excessive inventory.

Evaluate low-sorption and low-extractables packaging

Nelarabine is administered intravenously over a prolonged period in some dosing schedules. Packaging development should compare:

• Type I glass vials
• Cyclic olefin polymer containers
• Polyolefin infusion bags
• Standard versus low-sorption tubing
• Elastomer stopper formulations
• Different overwrap and light-protection systems

A packaging patent is more defensible when it links a specific material combination to a demonstrated result, such as reduced nelarabine loss, lower impurity formation, or extended in-use stability.

What formulations are protected by Arranon patents?

Public labeling does not identify a complex proprietary excipient platform for Arranon. The product’s formulation is a conventional sterile aqueous injectable composition. [1]

The potential intellectual-property categories are:

IP category	Relevance to nelarabine	Expected strategic value
Active-ingredient composition	Covers nelarabine or related compounds	Historical importance; likely expired or commercially weak
Process patents	Synthesis, purification, impurity control	Can affect API sourcing and quality
Formulation patents	pH, tonicity, concentration, stability	Potentially narrow unless tied to unexpected results
Container patents	Vial, bag, stopper, tubing, or closure system	Useful for differentiated presentations
Method-of-use patents	Treatment of T-ALL or T-LBL	Limited value where core therapeutic use is mature
Manufacturing know-how	Impurity limits, crystallization, scale-up	Important trade-secret barrier even without blocking patents

A new formulation filing should avoid claiming only "nelarabine plus sodium chloride in water." That type of claim is vulnerable to anticipation or obviousness challenges. More defensible claims would combine a defined composition with:

• A narrow pH window
• A specified degradation profile
• A defined shelf life
• A particular container closure system
• A dilution and administration protocol
• Reduced adsorption or reduced impurity growth
• A pediatric-use presentation that reduces preparation steps

When does Arranon lose exclusivity?

Arranon’s principal regulatory exclusivity is no longer the main commercial barrier. The FDA approved Arranon in October 2005 for relapsed or refractory T-cell malignancies. [2]

Exclusivity or barrier	Arranon status
FDA approval	October 2005
Orphan-drug exclusivity	Historical seven-year period; expired
Small-molecule regulatory exclusivity	Expired
Biosimilar exclusivity	Not applicable
Formulation exclusivity	No broad, high-complexity formulation moat identified from the label
Generic pathway	Potentially available through an ANDA if applicable requirements are met
Market barrier	Sterile manufacturing, API quality, limited demand, and oncology distribution

The relevant commercial question is therefore not when Arranon loses exclusivity. It is whether a supplier can manufacture and register nelarabine injection profitably at relatively low annual volume.

What is the Orange Book status of Arranon?

Arranon is a small-molecule drug and, if eligible generic applicants submit ANDAs, the relevant pathway is an abbreviated new drug application rather than a biosimilar application. The Orange Book identifies approved drug products and any listed patents or exclusivity information that affect generic certification. [3]

For commercial diligence, the Orange Book analysis should focus on:

1. Whether Arranon has current patent listings.
2. Whether any listed patent covers the drug substance, formulation, or method of use.
3. Whether a generic applicant must file a Paragraph IV certification.
4. Whether pediatric-use or orphan-related exclusivity blocks approval.
5. Whether any listed patent has an expiration date later than the principal compound rights.

A conventional nelarabine formulation would not automatically be blocked by historic patents covering the original discovery compound. Generic applicants must assess the current Orange Book record, patent-family status, and any litigation rather than relying on the branded product’s approval date alone. [3]

Are there Paragraph IV challenges to Arranon?

No major, widely reported Paragraph IV litigation strategy is associated with Arranon in the core public record used for this assessment. The commercial risk is more likely to arise from an ANDA with a Paragraph III or certification pathway, depending on any current Orange Book listings, than from a heavily contested formulation patent estate.

A Paragraph IV case would be most plausible if a listed patent covered:

• A specific nelarabine formulation
• A stability-enhancing excipient combination
• A particular intravenous administration method
• A later-developed ready-to-use presentation

A generic applicant could also avoid certain patents through a "skinny label" approach if the patent claims a method of use that can be carved out while retaining an approvable oncology indication. That analysis depends on the exact listed claims and FDA labeling.

Is biosimilar risk relevant to Arranon?

No. Nelarabine is a chemically synthesized small molecule, not a biologic. Biosimilar provisions under the Public Health Service Act do not apply. The relevant competitive threat is generic nelarabine injection under the Federal Food, Drug, and Cosmetic Act. [4]

This distinction affects:

• Development cost
• Clinical evidence requirements
• Interchangeability rules
• Patent certifications
• Substitution practices
• Time to market

A generic applicant would typically seek pharmaceutical equivalence and bioequivalence or applicable product-specific equivalence under the FDA’s ANDA framework. For an injectable product, formulation sameness, sterility, strength, route, and quality attributes are central.

What commercial opportunities exist for Arranon excipients?

Generic sterile injectable supply

The clearest opportunity is a generic nelarabine injection with the same basic excipient system. Demand is limited to a specialized oncology population, but competition may also be limited because sterile oncology products require:

• Validated aseptic or terminal-sterilization processes
• Qualified API supply
• Low particulate burden
• Reliable batch release
• Pharmacovigilance infrastructure
• Hospital and specialty-distributor access

The market is more attractive to a supplier that already operates an oncology injectable portfolio than to a new entrant building a single-product platform.

Pediatric-use optimization

Pediatric patients receive body-surface-area-based dosing. A formulation or packaging system that reduces partial-vial waste could create a practical purchasing advantage.

Potential approaches include:

• Smaller vial sizes
• Graduated presentations
• Pharmacy-ready unit doses
• Dose-banding compatibility
• Standardized dilution volumes
• Reduced residual volume
• Improved visibility of fill volume

The strongest value proposition is operational rather than pharmacological: fewer manipulations and less drug wastage.

Ready-to-administer oncology bags

A ready-to-administer bag could compete on pharmacy labor, administration consistency, and medication-error reduction. The product would need validated in-use stability, container compatibility, and a packaging configuration that accommodates body-surface-area dosing.

This opportunity is commercially stronger if the manufacturer has an existing hospital contract base and can bundle nelarabine with other oncology injectables.

Excipient and packaging supply

Excipient suppliers can participate without marketing nelarabine itself by providing:

• Parenteral-grade sodium chloride
• High-purity hydrochloric acid
• Water-for-injection systems
• Low-extractables elastomers
• Polymer infusion containers
• Low-sorption administration sets
• Container-closure testing
• Stability-indicating analytical methods

The excipient content per dose is modest, so raw-material sales alone are unlikely to support a large standalone opportunity. Higher-value services are more likely in formulation development, sterile filling, packaging, and analytical release.

Contract manufacturing

Contract development and manufacturing organizations can offer a complete package:

• Nelarabine API sourcing
• Aqueous formulation development
• Aseptic filling
• Packaging qualification
• Stability studies
• Regulatory documentation
• Commercial batch manufacture

Because Arranon’s formulation is relatively simple, manufacturing economics and regulatory execution may matter more than formulation novelty.

How strong is the Arranon patent estate?

The estate appears more vulnerable on formulation grounds than products based on liposomes, long-acting injectables, biologics, or device-enabled delivery.

Strengths

• Established clinical use
• FDA-approved injectable presentation
• Potential process know-how around API purity
• Possible barriers from sterile manufacturing and limited suppliers
• Specialized oncology distribution requirements

Weaknesses

• Simple excipient composition
• No apparent device-dependent delivery system
• No biosimilar-style complexity
• Mature regulatory history
• Limited basis for broad composition-of-matter protection at the product level
• Small market may attract only a narrow number of generic competitors

Patent strength should be separated from supply-chain strength. A weak formulation patent can coexist with a commercially durable product if API sourcing, sterile capacity, and market economics discourage entry.

What patent litigation affects Arranon?

No prominent current litigation involving the core Arranon formulation is identified in the principal public sources reviewed for this analysis. Litigation risk remains possible if a manufacturer obtains approval for a new formulation, container system, or method-of-use patent and then lists it in the Orange Book.

Potential disputes would likely concern:

• Paragraph IV certification
• Infringement of formulation claims
• Validity of pH or stability claims
• Skinny-label scope
• Induced infringement based on oncology prescribing
• Trade-secret misappropriation involving API manufacture
• Contract manufacturing and supply rights

A settlement agreement would have the greatest commercial impact if it included a licensed generic launch date, authorized-generic arrangement, supply commitment, or restrictions on a ready-to-use presentation. No material public settlement governing the core nelarabine market is identified here.

How does Arranon compare with competing T-cell leukemia drugs?

Arranon occupies a specialized position in relapsed or refractory T-cell malignancies. Its closest competitive comparisons are not formulation substitutes but alternative salvage regimens, combination chemotherapy, clinical trials, and hematopoietic stem-cell transplantation.

Attribute	Arranon	Broader oncology alternatives
Active ingredient	Nelarabine	Multiple unrelated agents
Modality	Small-molecule injectable	Oral drugs, injectables, biologics, cellular therapies
Excipient complexity	Low	Ranges from simple solutions to complex biologics
Regulatory pathway for follow-on	ANDA	ANDA, 505(b)(2), or biologic pathways
Biosimilar exposure	None	Relevant for biologic competitors
Administration	Intravenous infusion	Varies
Main differentiation	Disease-specific salvage use	Efficacy, toxicity, treatment setting, and combination utility
Formulation moat	Limited	Often stronger for biologics and complex delivery systems

The principal competitive advantage of a nelarabine generic would be price, availability, and pharmacy convenience rather than a new mechanism of action.

What generic launch scenarios exist for Arranon?

Scenario 1: Same-formulation vial

This is the lowest-risk entry model. The manufacturer matches the labeled strength and basic excipient profile, obtains approval, and competes on price and supply reliability.

Scenario 2: Same formulation with improved packaging

A supplier could use a lower-sorption bag, enhanced closure system, or smaller vial while preserving the underlying aqueous composition. The value would come from reduced waste and improved handling.

Scenario 3: Pharmacy-ready presentation

A ready-to-use bag or standardized dose presentation could support premium contracting with hospitals, provided the product reduces preparation costs enough to offset packaging and inventory costs.

Scenario 4: Limited commercial entry

A specialty manufacturer could supply a small number of hospitals or distributors without seeking broad market share. This model may be viable if demand is concentrated and manufacturing capacity is available.

What geographic coverage is available for nelarabine?

The United States is the key reference market for Arranon because FDA approval establishes the principal labeled use and product specifications. International opportunities depend on national approvals, local orphan-drug rules, reimbursement, and the availability of generic registration pathways.

A geographic expansion strategy should prioritize:

• Markets with established T-cell leukemia treatment centers
• Countries recognizing FDA or European regulatory data
• Regions with oncology injectable shortages
• Hospital systems using centralized pharmacy preparation
• Jurisdictions with manageable sterile-manufacturing requirements

Patent coverage is likely to vary by country and patent family. A U.S. patent or Orange Book result does not establish freedom to operate in Europe, Canada, Japan, or emerging markets.

What manufacturing and IP barriers exist for Arranon?

The principal barriers are operational:

• Qualified nelarabine API
• Control of related substances and degradation products
• Sterile filling capacity
• Validated container-closure systems
• Stability under distribution conditions
• Low-volume commercial economics
• Regulatory documentation for an injectable ANDA
• Hospital contracting and shortage management

The most valuable proprietary assets may be manufacturing know-how and analytical methods rather than broad excipient claims. A company seeking a defensible position should consider filing on a package of composition, process, container, and in-use stability claims, while maintaining detailed API and impurity-control methods as trade secrets.

Key Takeaways

• Arranon is a simple aqueous nelarabine injection containing sodium chloride, hydrochloric acid, and water for injection.
• Its commercial formulation does not present the complexity of a biologic, liposomal product, or long-acting injectable.
• The most realistic generic strategy is a same-formulation sterile vial.
• Ready-to-use bags, smaller vials, pediatric dose optimization, and low-waste packaging are the strongest commercial differentiation opportunities.
• Biosimilar competition does not apply; generic ANDA competition does.
• The main barriers are sterile manufacturing, API quality, supply reliability, and low-volume economics.
• A formulation patent strategy should rely on demonstrated stability, packaging, impurity, or administration advantages rather than routine excipient combinations.
• No major public Paragraph IV dispute or settlement is identified for the core Arranon formulation in the reviewed record.
• Revenue exposure is concentrated in a specialized relapsed or refractory T-cell malignancy market, limiting total volume but potentially supporting premium supply reliability and hospital-contracting value.

FAQs

Can nelarabine be reformulated as an oral product?

An oral nelarabine product would require a separate formulation and clinical-development strategy. The existing Arranon approval is for intravenous administration, and an oral product would not qualify as a routine injectable generic.

Is sodium chloride essential to the Arranon formulation?

Sodium chloride is identified in the U.S. product labeling as an inactive ingredient. A follow-on product could require formulation justification if it changed tonicity or replaced sodium chloride with another excipient.

Could a 505(b)(2) application compete with Arranon?

Potentially, if the product introduced a meaningful formulation, concentration, delivery, or administration change that could not be supported through a conventional ANDA. A simple copy of the approved injection would generally be better suited to the ANDA pathway.

What is the most valuable improvement for pediatric hospitals?

A smaller-volume or pharmacy-ready presentation that reduces partial-vial waste and aseptic preparation steps is likely to have more practical value than a new excipient system.

Could a nelarabine manufacturer obtain new Orange Book patents?

A manufacturer could seek patent protection for qualifying later-developed formulations, containers, manufacturing processes, or methods of use. Listing eligibility and enforcement would depend on the patent claims and FDA Orange Book requirements.

References

1. U.S. Food and Drug Administration. (2023). Arranon (nelarabine) injection: Prescribing information.
2. U.S. Food and Drug Administration. (2005). FDA approves Arranon for T-cell malignancies.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application approvals and generic drug development.